TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum

Rhea-AI Summary

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer and other conditions, has announced its CEO Bryan Kobel's upcoming participation in the Cancer Progress Panel at the 18th Annual European Life Sciences CEO Forum.

The panel discussion is scheduled for February 27th, 2025, at 1:10 pm CET at the Hilton Zurich Airport Hotel. The forum, taking place on February 26-27, 2025, will feature over 12 hours of high-level keynotes and panel discussions, including HealthTech topics such as AI, convergence, and diagnostics.

The event will showcase more than 50 presentations from public, private, emerging, and seed companies seeking investment and partnering opportunities in innovative healthcare solutions.

EDINBURGH, Scotland , Feb. 20, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) , a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its CEO will join the Cancer Progress Panel discussion on February 27^th at 1:10 pm CET at the 18th Annual European Life Sciences CEO Forum, which will include HealthTech topics such as AI, convergence, and diagnostics.

The forum will take place on the 26th - 27th of February 2025 at the Hilton Zurich Airport Hotel. The main programme for the 18th Annual ELSF will feature more than 12 hours of high-level keynotes and panel discussions. 

Additionally, there will be a global company showcase of 50+ presentations by established public, private, emerging, and seed companies, offering innovative solutions and seeking investment and partnering opportunities. For more information about the 18th Annual European Life Sciences CEO Forum, please click here.

About TC BioPharm (Holdings) PLC

TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.

TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.

Forward-Looking Statements for TC BioPharm

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum-302380543.html

SOURCE TC BioPharm

FAQ

When will TCBP CEO present at the European Life Sciences CEO Forum 2025?

TCBP CEO Bryan Kobel will participate in the Cancer Progress Panel on February 27th, 2025, at 1:10 pm CET at the Hilton Zurich Airport Hotel.

What topics will be covered at the 2025 European Life Sciences CEO Forum where TCBP is presenting?

The forum will cover HealthTech topics including AI, convergence, and diagnostics, featuring over 12 hours of high-level keynotes and panel discussions.

How many companies will be presenting at the 2025 European Life Sciences Forum alongside TCBP?

More than 50 companies, including public, private, emerging, and seed companies, will be presenting at the forum.

What is TCBP's current development focus in cancer treatment?

TCBP is developing platform allogeneic gamma-delta T cell therapies for cancer and other indications as a clinical-stage biotechnology company.